Is Xarelto approved for treating venous thromboembolism and preventing pulmonary embolism?

Xarelto (rivaroxaban) is a direct oral anticoagulant that works by blocking factor Xa, a key protein in blood clotting. It is approved by the FDA for several uses, including the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for reducing the risk of recurrent DVT and PE. This means it is a standard option for managing venous thromboembolism (VTE) and preventing PE.

What the research says

The FDA label for Xarelto explicitly lists its approval for the treatment of DVT and PE, and for reduction in the risk of recurrence of DVT or PE ⁵. This is supported by large clinical trials. In the EINSTEIN-DVT and EINSTEIN-PE trials, which included over 8,000 patients, rivaroxaban was shown to be as effective as standard therapy (enoxaparin followed by a vitamin K antagonist) for preventing recurrent VTE after 3, 6, or 12 months of treatment ⁷. Notably, when data from these trials were pooled, rivaroxaban was associated with a significantly lower rate of major bleeding compared to standard therapy ⁷. Another review confirms that rivaroxaban is approved for the prevention and treatment of DVT and PE, and for the prevention of VTE after hip or knee replacement surgery ⁸. A separate review also states that rivaroxaban is approved for treatment and prevention of PE and DVT ⁹. In a study of cancer patients with low-risk PE, home treatment with rivaroxaban showed a 4.6% rate of major bleeding, with no cases of PE-related death or recurrent VTE ⁶.

What to ask your doctor

• Is Xarelto a good option for treating my DVT or PE?
• How long would I need to take Xarelto to prevent recurrence?
• What are the signs of bleeding I should watch for while on Xarelto?
• Are there any interactions with my other medications or supplements?
• Should I have any follow-up tests, like D-dimer or ultrasound, to guide treatment duration?